Forte has announced significant updates to its eReg solution, which allows sites to compliantly manage multi-site trials. These additional eReg capabilities also serve as the foundation for the regulatory component of Forte's Trial Data Exchange, an open, secure collaboration and data sharing platform feature that gives sites and sponsors the ability to collaborate, share trial-specific data on demand, and structure necessary controls for access to regulatory, operational and clinical source data.
Developed in concert with academic research organizations-and eReg users-like Yale, The Ohio State University, and Karmanos Cancer Institute, eReg now offers multi-site trial management capabilities that will enable industry-wide research collaboration. Forte eReg customers are able to track and manage their investigator-initiated trials and streamline workflows across individual research sites more cohesively. Customers will now be able to maximize compliance, data security, and efficiency of their full portfolio of studies across all departments within an organization and collaborate with sponsors on data and trial progress.
James Wurdeman, Chief Product Officer at Forte, said, "Our commitment remains to arm the clinical research industry with secure, powerful and flexible technology. Today's eReg announcement is proof positive that important, game-changing progress is happening, and true industry-wide collaboration and compliance will become a reality in the near future."
Specific eReg features that have been added to Forte's platform include:
"Forte's eReg system is an integral part of our mission of a seamless clinical research management process. The system was built for the community, by the community, and we are thrilled to be one of the research institutions that collaborated to help build eReg from the ground up," said Robb Stillman, Director, Research & Clinical Informatics at The Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute. "The implementation of eReg provides multifaceted benefits, including integration with Forte's OnCore Enterprise Research System, simplified document management and most importantly, increased compliance across our research portfolio. We're also thrilled for the addition of multi-site management-this will be a valuable addition for organizations like OSU, streamlining our compliance processes, reducing the burden for our regulatory staff and improving data quality across all the multi-site trials we coordinate."
Forte's new features will be available to all eReg customers in Q3.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.